Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 10, 2007, Pages 1915-1917

  Zhang, Hui ^a   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR ANTIGEN;

BLOOD SAMPLING; CANCER TISSUE; EDITORIAL; PRIORITY JOURNAL; PROTEOMICS;

HUMANS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROTEIN TRANSPORT; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 35448955641     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0420     Document Type: Editorial

References (27)

1. Chan DW, Schwartz MK. Tumor markers: Introduction and general principles. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers: physiology, pathology, technology and clinical applications. Washington (DC): AACC Press; 2002. p. 9-18.
2. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
3. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
4. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
5. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
6. Liang SL, Chan DW. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clin Chim Acta 2007;381:43-7.
7. Li J, Zhao J, Yu X, et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005;11:8312-20.
8. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
9. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005;51:2229-35.
10. Coombes KR. Analysis of mass spectrometry profiles of the serum proteome. Clin Chem 2005;51:1-2.
11. Vejda S, Posovszky C, Zelzer S, et al. Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis. Mol Cell Proteomics 2002;1:387-93.
12. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-45.
13. States DJ, Omenn GS, Blackwell TW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006;24:333-8.
14. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
15. Zhang H, Yi EC, Li XJ, et al. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics 2005;4:144-55.
16. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
17. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 2005;102:10852-7.
18. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003;61:132-6.
19. Lorente JA, Arango O, Bielsa O, Cortadellas R, Gelabert-Mas A. Effect of antibiotic treatment on serum PSA and percent free PSA levels in patients with biochemical criteria for prostate biopsy and previous lower urinary tract infections. Int J Biol Markers 2002;17:84-9.
20. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6.
21. Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007;6:64-71.
22. Pan S, Zhang H, Rush J, et al. High throughput proteome screening for biomarker detection. Mol Cell Proteomics 2005;4:182-90.
23. Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 2005;6:577-83.
24. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
25. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
26. Zhang H, Yan W, Aebersold R. Chemical probes and tandem mass spectrometry: a strategy for the quantitative analysis of proteomes and subproteomes. Curr Opin Chem Biol 2004;8:66-75.
27. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Nat Cancer Inst 2001;93:1054-61.